請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/36032
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 江伯倫(Bor-Luen Chiang) | |
dc.contributor.author | Chia-Lin Hsu | en |
dc.contributor.author | 徐家琳 | zh_TW |
dc.date.accessioned | 2021-06-13T07:50:02Z | - |
dc.date.available | 2007-08-18 | |
dc.date.copyright | 2005-08-18 | |
dc.date.issued | 2005 | |
dc.date.submitted | 2005-07-25 | |
dc.identifier.citation | Abbas, A.K., Lohr, J., Knoechel, B., and Nagabhshanam, V. (2004). T cell tolerance and autoimmunity. Autoimmunity 3, 471-475.
Aluvihare, V.R., Kallikourdis, M., and Betz, A.G. (2004). Regulatory T cells mediate maternal tolerance to the fetus. Nat. Immunol. 5, 266-271. Anderson, K. C., Boise, L. H., Louie, R., and Waxman, S. (2002). Arsenic trioxide in multiple myeloma: Rationale and future directions. Cancer J. 8, 12–25. Bennett, C.L. (2001). The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 27,20-21 Bernstam, L., and Nriagu, J. (2000). Molecular aspects of arsenic stress. J. Toxicol. Environ. Health B Crit. Rev. 3, 293-322. Bernstein, K.A., Valerio, R.D., and Lefkowith, L.B. (1995). Glomerular binding activity in MRL/lpr serum consists of antibodies that bind to DNA/histone/type IV collagen complex. J. Immunol. 154, 2424-2433. Bettelli, E., Dastrange, M., and Okuka, M. (2005). Foxp3 interacts with nuclear factor of activated T cells and NF-κB to repress cytokine gene expression and effector functions of helper cells. Proc. Natl. Acad. Sci. USA 102, 5138-5143. Bruder, D., Probst-Kepper, M., Westendorf, A.D., Geffers,R., Beissert, S., Loser, K., Boehmer, H.V., Buer, J., and Hansen, W. (2004). Neuropilin-1: a surface marker of regulatory T cells. Eur. J. Immunol. 34, 623–630. Brunkow, M.E., Jeffery, E.W., Hjerrild, K.A., Paeper, B., Clark, L.B., Yasayko, S., Wilkinson, J.E., Galas, D., Ziegler, S.F., and Ramsdell, F. (2001). Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat. Genetics 27, 68-73. Caramalho, I., Lopes-Carvalho, T., Ostler, D., Zelenay, S., Haury, M., and Demengeot, J. (2003). Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. J. Exp. Med. 197, 403-411. Casciola-Rosen, L.A., Anhalt, G., and Rosen, A. (1994). Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J. Exp. Med. 179, 1317-1330. Chatila, T.A. (2000). JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J. Clin. Invest. 106, R75-R81. Coffer, P.J., and Burgering, B.M.T. (2004). Forkhead-box transcription factors and their role in the immune system. Nat. Rev. Immunol. 4, 889-899. Crispin, J.C., Martinez, A., and Alcocer-Varela, J. (2003). Quantificaion of regulatory T cells in patients with systemic lupus erthrmatosus. J. Autoimmu. 21, 273-276 Csiszar, A., Nagy, G., and Gergely, P. (2000). Increased interferon-gamma (IFN-gamma), IL-10 and decreased IL-4 mRNA expression in peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin. Exp. Immunol. 122, 464-470. Douer, D., and Tallman, M.S. (2005). Arsenic trioxide: new clinical experiment with an old medicine in hematologic malignancies. Journal of Clinical Oncology 23, 2396-2410. Finck, B.K., Linsley, P.S., and Wofsy, D. (1994). Treatment of murine lupus with CTLA4 Ig. Science 265, 1225-1227. Fontenot, J.D., and Rudensky A.Y. (2005). A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat. Immunol. 6, 331-337. Fontenot, J.D., Gavin, M.A., and Rudensky, A.Y. (2003). Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4, 330-336. Fontenot, J.D., Rasmussen, J.P., Williams, L.M., Dooley, J.L., Farr, A.G., and Rudensky, A.Y. (2005). Regulatory Tcell lineage specification by the forkhead transcription factor Foxp3. Immunity 22, 329-341. Grondal, G., Gunnarsson, I., and Ronnelid, J. (2000). Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin, Exp. Rheumatol. 18, 565-570. Herrmann, M., Voll, R.E., and Zoller, O.M. (1998). Impaired phagocytosis of apoptosis cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum. 41, 1241-1250. Hori, S., Nomura, T., and Sakaguchi, S. (2003). Control of regulatory T cell development by the transcription factor Foxp3. Science 299, 1057-1061. Hoewitz, D.A., Zheng, S.G., Gray, J.D., Wang, J.H., Ohtsuka, K., and Yamagiwa, S. (2004). Regulatory T cells generated ex vivo as an approach for the therapy of autoimmune disease. Sem. in Immunol. 16, 135-143. Houssiau, F.A., Lefebvre, C., and Vanden, B.M. (1995). Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus 4, 393-395. Jonuleit, H., and Schmitt, E. (2003). The regulatory T cell family: distinct subsets and their interrelations? J. Immunol. 6323-6327. Kaestner, K.H., Knochel, W., and Martinez, D.E. (2000). Unifired nomenclature for the winged helix/forkhead transcription factors. Gene Dev. 14, 142-146 Khattri, R., Cox, T., Yasayko, S., and Ramsdell, F. (2003). An essential role for scurfin in CD4+CD25+ T regulatory cells. Nat. Immunol. 4, 337-342. Klein, L., Khazaie, K., and Von Boehmer, H. (2003). In vivo dynamics of antigen-specific regulatory T cells not predicted from behavior in vitro. Proc. Natl. Acad. Sci. USA. 100, 8886-8891. Kotzin, B.L. (1996). Systemic lupus erythematosus. Cell 85, 303-306. Levings, M.K., and Roncarolo M.G. (2000). T-regulatory 1 cells: a novel subset of CD4 T cells with immunoregulatory properties. J. Allergy Clin. Immunol. 106, S109-112. Liu, M.F., Wang, C.R., Fung, L.L., and Wu, C.R. (2004). Decreased CD4+CD25+ T cells in peripheral blood of patient with systemic lupus erythematosus. Scan. J. Immunol. 59, 198-202 Logan, A.C., Lutzko, C., and Kohn, D.B. (2002). Advances in lentiviral vector design for gene-modification of hematopoietic stem cells. Current Opin. Biotechnol. 13, 429–436. Miller, W.H., Jr., Schipper, H.M., Lee, J.S., Singer, J., and Waxman, S. (2002). Mechanisms of action of arsenic trioxide. Cancer Research. 62, 3893-3903. Mok, C.C., and Lau, C.S. (2003). Pathogenesis of systemic lupus erythematosus. J. Clin. Pathol. 56, 481-490. Nishizuka, Y. and Sajaguchi, S. (1969). Thymus and reproduction: sex-linked dysgenesia of the gonad after neonatal thymectomy in mice. Science 166, 753-755. Piccirillo, C.A., and Thornton, A.M. (2004). Cornerstone of peripheral tolerance: naturally occurring CD4+CD25+ regulatory T cells. Trends in Immunol. 25, 374-380. Robson, M.G., and Walport, M.J. (2001). Pathogenesis of systemic lupus erythematosus (SLE). Clin. Exp. Allergy 31, 678-685. Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., and Toda, M. (1995). Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). J. Immunol. 155, 1151-1164. Sakaguchi, S. (2004). Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22, 531-562. Schur, P.H. (1995). Genetics of systemic lupus erythematosus. Lupus 4, 425-437. Schurbert, L.A., Jeffery, E., Zhang, Y., Ramsdell, F., and Ziegler, S.F. (2001). Scurfin (FOXP3) acts as a repressor of transcription and regulates T cell activation. J. Biol. Chem. 276, 37672-37679. Schwartz, R.H. (2005). Natural regulatory T cells and self-tolerance. Nat. Immunol. 6, 327-330. Setoguchi, R., Hori, S., Takahashi, T., and Sakaguchi, S. (2005). Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. 201,723-35 Shevach, E.M. (2002). CD4+CD25+ suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2, 389-400. Snow, E. T. (1992). Metal carcinogenesis: mechanistic implications. Pharmacol. Ther., 53,31–65. Suen J.L., Chuang Y.H., and Chiang B.L. (2002). In vivo tolerance breakdown with dendritic cells pulsed with U1A protein in non-autoimmune mice: the induction of a high level of autoantibodies but not renal pathological changes. Immunology 106, 326-335. Theofilopoulos, A.N., and Lawson, B.R. (1999). Tumour necrosis factor and other cytokines in murine lupus. Ann. Rheum. Dis. 58, 49i. Thornton, A.M., Donovan, E.E., Piccirillo, C.A., and Shevach, E.M. (2004). Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J. Immunol. 172, 6519-6523. Wakeland, E.K., Wandstrat, A.E., Liu, K., and Morel. L. (1999). Genetic dissection of systemic lupus erythematosus. Curr. Opin. Immunol. 11, 701-707. Uslu, R., Sanli, U. A., Sezgin, C., Karabulut, B., Terzioglu, E., Omay, S. B., and Goker, E. (2000). Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin. Cancer Res., 6: 4957–4964. Walker, L.S.K., Chodos, A., Eggena, M., Dooms, H., and Abbas, A.K. (2003). Antigen-dependent proliferation of CD4+Cd25+ regulatory T cells in vivo. J. Exp. Med. 198, 249-258. Zheng, S.G., Koss, M.N., Quismorio, F.P., Wang, J.H., Gray, J.D., and Howartz, D.A. (2004). CD4+ and CD8+ regulatory T cells generated ex-vivo with IL-2 and TGF-beta suppress a stimulatory graft-versus-host-disease with a lupus-like syndrome. J. Immunol. 173, 1531-1539. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/36032 | - |
dc.description.abstract | 紅斑性狼瘡(systemic lupus erythematosus, SLE)是一種多重器官受損的自體免疫疾病,其致病因素很多,包括調節一些可以對自體抗原產生免疫反應淋巴細胞的功能有缺陷。在我的第一部份的研究,我們想要探討是否調節性T細胞可以減緩病徵。
Foxp3是一個專一表現在CD4+CD25+調節性T細胞中的轉錄調節因子,在調節性T細胞的發育和功能上是一個重要的調節基因。若將Foxp3送入CD4+CD25-非調節性T細胞中,會使其具有像自然產生的調節性T細胞一樣具有免疫抑制的功能。目前我們已知調節性T細胞的免疫抑制功能調控許多有自體或非自體抗原所引起的免疫反應。在此研究中,我們想要探究如果將Foxp3過度表現的T細胞送入紅斑性狼瘡小鼠中(NZB/NZW F1),是否具有減緩降低病情的效用。 我們首先從正常老鼠(DBA2/NZW F1)分離純化出CD4+CD25+ T細胞當作正常的調性T細胞,並且利用尾靜脈注射移植到紅斑性狼瘡小鼠中。藉由觀察抗自體抗體的產生程度,我們發現有移植調節性T細胞的小鼠,其抗自體抗體的濃度在大約一個月後開始下降,且抑制功能可以維持三個月之久。接下來我們想要在體外大量產生調節性T細胞,我們利用反轉錄病毒(lentivirus)將Foxp3帶入CD4+CD25- T細胞中使其具有抑制功能,這部份的實驗仍在進行中。 在第二部份的實驗中,我們想知道常被用來作為抗癌藥劑的砒霜(As2O3),是否也能減緩紅斑性狼瘡小鼠的病徵。我們利用腹腔注射給予不同濃度的砒霜,一個星期給三次,總共給予兩個月。我們發現,在第一次注射一個月之後,給予高劑量砒霜的小鼠,其抗自體抗體的濃度明顯地比給予對照緩衝液的組別來的低。而且有給予砒霜的小鼠其腎絲球發炎(GN)的情形比較輕微,並且能活的比較久。 由上述實驗可知,不管是異體移植調節性T細胞或是給予砒霜,都有助於紅斑性狼瘡小鼠的病情,能減緩其病徵。這些方法未來可以應用在臨床上的治療。 | zh_TW |
dc.description.abstract | Systemic lupus erythematosus (SLE) is a multiple organic autoimmune disease, which caused by has many pathogenic factors including defect in regulation of autoreactive lymphocytes. In the first part of the study, we aimed to study whether regulatory T cells could alleviate disease severity of lupus. Foxp3, a forkhead transcription factor, specifically expressed in CD4+CD25+ regulatory T cells (Treg) is a key regulatory gene for development and function of Treg. Foxp3-transfected CD4+CD25- T cells have immunosuppressive function as nature occurring CD4+CD25+ regulatory T cells. It has been well known that Treg have suppressive function and can control several immune responses caused by self or non-self antigens. In this study, we like to investigate if we can deliver the Foxp3-overexpressed T cells for the alleviation of disease severity in murine lupus.
We first isolated CD4+CD25+ T cells isolated from nonautoimmune DBA2/NZW F1 mice and adoptively transferred to NZB/NZW F1 mice, which spontaneously develop lupus. By assaying antibodies against dsDNA and ssDNA, we found that these cells could decrease the level of autoantibodies comparing to control mice. The therapeutic effects were seen one month after transfer, and could sustain for three months. We further wanted to induce regulatory T cells by infected CD4+CD25- T cells with Foxp3-expressing lentivirus. We have concentrated the lentivirus vector expressing Foxp3 gene, however, the in vivo study is yet to be finished. In the second part of the study, we would like to know whether arsenic trioxide (As2O3), a well known anticancer agent, could alleviate disease severity of SLE. We intraperitoneally injected different dose of arsenic trioxide to NZB/NZW F1 mice three days a week for two months. It was found that, one month after injection of arsenic trioxide the level of autoantibodies was lowered comparing to mice of control group. And the percentage of severe glomerulonephritis (GN) was lower in treatment groups. In addition, mice injected with arsenic trioxide were lived longer than mice injected with PBS only. Both adoptive transfers of CD4+CD25+ regulatory T cells and treatment of arsenic trioxide could alleviate the disease severity in lupus mice. In the future, these therapeutic approaches may be applied to clinical purposes. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T07:50:02Z (GMT). No. of bitstreams: 1 ntu-94-R92449003-1.pdf: 1311368 bytes, checksum: 436abc6d1e9b2764a3dd9ab75624f184 (MD5) Previous issue date: 2005 | en |
dc.description.tableofcontents | 標題………………………………………………………..….……... i
口試委員會審定書……………………………………….…..…….. ii 授權書………………………………………………………...……... iii 誌謝………………………………………………………………….. iv 中文摘要……………………………………………….......………... vi ABSTRACT …...……………………………………...….………..... viii CONTENTS…………………………………………………………. x PART I………………………………………………………………. 1 CHAPTER I General Introduction………………….……………... 2 1.1 Background…………………………………………………. 3 1.2 Hypothesis………………………………. …………………. 15 1.3 Specific aim……………………………………………..…... 15 1.4 Siginificance………………………………………………... 15 CHAPTER II Materials and Methods……………………………... 16 2.1 Reagents…………….…………………………….………… 17 2.2 Mice………………………….……………………………... 22 2.3 Cell lines……………………………………………………. 23 2.4 Exploration of immunotherapy……………………………... 23 2.5 Transfection of primary T cells by lentiviral vector with Foxp3………………………………………...… 29 CHAPTER III Results………………….……………………….…. 35 3.1 immunotherapy analysis……………………………………. 36 3.2 Transfection of primary T cells by lentiviral vector……….. 39 CHAPTER IV Discussion and Perspectives…………….………… 43 PART II……………………………………………………………… 63 CHAPTER I General Introduction………………….……………... 64 1.1 Background…………………………………………………. 65 1.2 Specific aim……………………………………………..…... 67 CHAPTER II Materials and Methods……………………………... 68 2.1 Reagents…………….…………………………….…………. 69 2.2 Mice…………………………………………………………. 70 2.3 Methods……………………………………………………… 70 CHAPTER III Results………………….……………………….…. 73 REFERENCES……………………………………………….……… 79 Appendix…………………………………………………………….. 89 | |
dc.language.iso | en | |
dc.title | 調節性T細胞在狼瘡小鼠疾病的免疫調控中所扮演的角色 | zh_TW |
dc.title | The Role of Regulatory T cells in the Immune Modulation of Disease Activity in Murine Lupus | en |
dc.type | Thesis | |
dc.date.schoolyear | 93-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 繆希椿,孫光蕙 | |
dc.subject.keyword | 調節,狼瘡,免疫, | zh_TW |
dc.subject.keyword | regulatory T cell,lupus, | en |
dc.relation.page | 90 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2005-07-26 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 免疫學研究所 | zh_TW |
顯示於系所單位: | 免疫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-94-1.pdf 目前未授權公開取用 | 1.28 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。